Linklaters advises Jacobs Capital on the disposal of Stingray Healthcare to Amethyst Radiotherapy

Linklaters has advised European investment firm Jacobs Capital, on its disposal of Stingray Healthcare to pan-European radiotherapy provider Amethyst Radiotherapy, a portfolio company of Fremman Capital. 

With core operations in Germany and France, Stingray Healthcare operates cancer treatment centres across Europe through partnerships with cancer care professionals, providing financial resources and strategic expertise. 

The cross-practice Linklaters team was led out of London by Private Equity Partner Ben Rodham, Managing Associate Martin Arnal and Associate Louisa Pratt, supported by Tax Partner Jamie Coomber and Leveraged Finance Partner Thomas Waller. 

Cross-jurisdiction support was provided in Brussels by Antitrust Partner Neil Hoolihan and Managing Associate Karolis Pocius, and in Luxembourg by Corporate Counsel Maxime Bertomeu-Savalle and Managing Associate Aurelie Mounier.